Key result
Myotubes carrying the RyR1 Thr2206Met mutation showed increased sensitivity to 4-chloro-m-cresol (EC50 98 vs 203 µM) and caffeine (EC50 1.8 vs 3.8 mM) compared to wild type.
Absolute Event Rate: 98% vs 203%
The RyR1 Thr2206Met mutation increases sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes, indicating it is pathogenic for malignant hyperthermia.
Functional myotube studies support additional RYR1 variants as MH-causative; leaves open expanded genetic screening pending larger validation.
Malignant hyperthermia (MH) is an autosomal-dominant disorder of skeletal muscle, triggered by volatile anaesthetics and depolarizing muscle relaxants. The causative defect lies in the control of Ca(2+) release from the sarcoplasmic reticulum in skeletal muscle. Numerous mutations have been detected in the ryanodine receptor 1 (RyR1) gene, but so far an MH-causative role has only been confirmed for 16 human RyR1 mutations. In this report we show that myotubes derived from individuals carrying the RyR1 Thr2206Met (C6617T) mutation have an abnormal response of the intracellular calcium concentration to 4-chloro-m-cresol and to caffeine. Satellite cells were obtained from muscle biopsies of patients referred for diagnosing MH. The intracellular calcium concentration in response to 4-chloro-m-cresol and to caffeine was investigated by fluorescence calcium imaging. In myotubes the half-maximal activation concentration (EC(50)) for 4-chloro-m-cresol was reduced from 203 micro m (wild type) to 98 micro m (Thr2206Met), and for caffeine from 3.8 mm to 1.8 mm. From the reduction of EC(50) we conclude that the RyR1 Thr2206Met mutation is pathogenic for MH.
No takes yet. Share an insight, caveat, or question.
Wehner et al. (2002) studied Malignant hyperthermia. RyR1 Thr2206Met (C6617T) mutation vs. Wild type was evaluated on Half-maximal activation concentration (EC50) for 4-chloro-m-cresol (micro m). Myotubes carrying the RyR1 Thr2206Met mutation showed increased sensitivity to 4-chloro-m-cresol (EC50 98 vs 203 µM) and caffeine (EC50 1.8 vs 3.8 mM) compared to wild type.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: